MannKind Past Earnings Performance
Past criteria checks 2/6
MannKind has been growing earnings at an average annual rate of 11.4%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 31.8% per year.
Key information
11.4%
Earnings growth rate
17.4%
EPS growth rate
Biotechs Industry Growth | 18.9% |
Revenue growth rate | 31.8% |
Return on equity | n/a |
Net Margin | 4.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MannKind makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 248 | 12 | 91 | 41 |
31 Mar 24 | 225 | 8 | 93 | 36 |
31 Dec 23 | 199 | -12 | 94 | 31 |
30 Sep 23 | 177 | -31 | 96 | 29 |
30 Jun 23 | 158 | -47 | 95 | 23 |
31 Mar 23 | 128 | -71 | 95 | 22 |
31 Dec 22 | 100 | -87 | 91 | 20 |
30 Sep 22 | 76 | -98 | 92 | 16 |
30 Jun 22 | 66 | -88 | 87 | 16 |
31 Mar 22 | 70 | -94 | 81 | 13 |
31 Dec 21 | 75 | -81 | 77 | 12 |
30 Sep 21 | 81 | -79 | 72 | 10 |
30 Jun 21 | 75 | -86 | 68 | 8 |
31 Mar 21 | 66 | -61 | 62 | 7 |
31 Dec 20 | 65 | -57 | 59 | 6 |
30 Sep 20 | 63 | -45 | 58 | 7 |
30 Jun 20 | 62 | -44 | 60 | 7 |
31 Mar 20 | 62 | -46 | 63 | 7 |
31 Dec 19 | 63 | -52 | 75 | 7 |
30 Sep 19 | 63 | -47 | 77 | 6 |
30 Jun 19 | 53 | -61 | 80 | 6 |
31 Mar 19 | 42 | -71 | 85 | 8 |
31 Dec 18 | 28 | -87 | 80 | 9 |
30 Sep 18 | 16 | -110 | 85 | 11 |
30 Jun 18 | 13 | -119 | 83 | 13 |
31 Mar 18 | 12 | -131 | 80 | 14 |
31 Dec 17 | 11 | -117 | 75 | 14 |
30 Sep 17 | 20 | -31 | 67 | 12 |
30 Jun 17 | 180 | 129 | 62 | 12 |
31 Mar 17 | 178 | 134 | 55 | 18 |
31 Dec 16 | 175 | 126 | 47 | 15 |
30 Sep 16 | 162 | -205 | 38 | 20 |
30 Jun 16 | 0 | -364 | 35 | 21 |
31 Mar 16 | 0 | -363 | 35 | 19 |
31 Dec 15 | 0 | -368 | 41 | 30 |
30 Sep 15 | 0 | -128 | 44 | 39 |
30 Jun 15 | 0 | -133 | 53 | 54 |
31 Mar 15 | 0 | -177 | 75 | 83 |
31 Dec 14 | 0 | -198 | 79 | 100 |
30 Sep 14 | 0 | -216 | 84 | 112 |
30 Jun 14 | 0 | -230 | 83 | 120 |
31 Mar 14 | 0 | -203 | 65 | 110 |
31 Dec 13 | 0 | -191 | 60 | 110 |
Quality Earnings: NNFN has a large one-off loss of $9.7M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: NNFN became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NNFN has become profitable over the past 5 years, growing earnings by 11.4% per year.
Accelerating Growth: NNFN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NNFN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.08%).
Return on Equity
High ROE: NNFN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.